Navigation Links
Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
Date:2/6/2008

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, planned clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
2. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
3. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
4. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
5. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
7. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
8. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
10. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
11. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015  The Myeloma Crowd ... the selection of ten proposals that will now ... the first patient-led, scientifically validated funding initiative uncovering ... Stage 2 of the MCRI included preliminary vetting ... of a large number of innovative projects focusing ...
(Date:3/31/2015)... March 31, 2015 Diasome Pharmaceuticals, Inc. ... SDG, Inc., that a United States patent has recently ... therapy. , Entitled “Lipid Construct for Delivery ... of matter claims related to the use of Diasome’s ... enabling injected insulin to more effectively reach the liver’s ...
(Date:3/30/2015)... & Struggles (Nasdaq: HSII ), the premier provider of ... culture shaping worldwide, today  announced that John Mitchell ... and Life Sciences practice. As Global Practice Managing ... team of more than 80 partners, principals and associates in ... Asia serving clients in the biopharmaceutical, medical technology ...
(Date:3/30/2015)... 30, 2015 /CNW/ - A new national Labour Market ... and demographic profiles of new graduates entering the biotech ... Building Careers for New Grads in Biotech," is sponsored ... Pharmaceutical Companies (Rx&D) and features data collected from new ... subsidy program from 2013 to 2015. Among ...
Breaking Biology Technology:Myeloma Crowd Research Initiative Selects 10 High-Risk Multiple Myeloma Proposals For Further Review 2Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4
... Savvier consumers and competition from generic drugs have made ... maturity, more elusive.  At the same time, new technologies ... to support pharmaceutical brand growth. While biopharma ... brands, recent field research from Best Practices, LLC suggests ...
... 30, 2011 Amnis Corporation, a manufacturer of advanced cell ... by EMD Millipore, the Life Science division of Merck KGaA ... closing is expected to take place in the fourth quarter ... Amnis generated sales of USD 14 million ...
... crucial to preventing countless human diseases. In a recent ... a new approach for studying molecules within their natural ... how bacteria infect people. The research, led by ... in the Proceedings of the National Academy of ...
Cached Biology Technology:Using Public Relations to Launch, Grow, and Extend Pharmaceutical and Biotech Brands 2Amnis Acquired by EMD Millipore - Expands Growth Potential 2Amnis Acquired by EMD Millipore - Expands Growth Potential 3Scientists develop new technologies for understanding bacterial infections 2Scientists develop new technologies for understanding bacterial infections 3
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/12/2015)... , March 12, 2015 The mascots of ... Children,s Hospital, part of Wake Forest Baptist Medical Center. ... for the 2015 ACC Men,s Basketball Tournament. Young patients ... them and getting their autographs. Brenner Children,s ... It is the only children,s hospital in northwest ...
(Date:3/10/2015)... -- Continuing its 167-year history of offering the Best, the ... Eye Scanning Password Authenticator , a device that confirms ... or sensitive data. Employing the same biometric ... device has a small camera that scans and saves ... them into an encrypted ID that cannot be forged ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... Tenn., April 21, 2008 Improved management of crops ... the problem of hypoxia, which claims thousands of fish, ... spring. An assessment by a team led by ... Division concludes that low oxygen levels in water, or ...
... Virginia Bioinformatics Institute (VBI) at Virginia Tech and their ... family of virulence proteins that play an important role ... pathogen Phytophthora sojae. VBI Professor Brett Tyler ... from Virginia Techs Department of Plant Pathology, Physiology and ...
... results of a University of Illinois study have demonstrated an ... bars. Eating two CocoaVia dark chocolate bars a day ... also lowering systolic blood pressure, said John Erdman, a U. ... The study, funded in part by Mars Inc., the company ...
Cached Biology News:Crop management strategies key to a healthy Gulf, planet 2Crop management strategies key to a healthy Gulf, planet 3Chocolate bar shown to lower cholesterol 2
... The Ph.D. Peptide Display Cloning System ... on the surface of bacteriophage M13 as ... between each displayed peptide and its encoding ... of targets can then be selected by ...
... Detection of the yolk protein Vtg in ... simple and sensitive biomarker for endocrine disrupting chemicals ... Vtg has become an accepted screening test for ... Vtg (rainbow trout) EIA kit is a double-antibody ...
... synthetic peptide whose sequence corresponds to residues 115-133 of rat SAP97. ... V115 - L - P - S - E - ... - P - N - E - V - L - ... added to facilitate conjugation and is not a part of the ...
... Rapid-Screen cDNA Library Panels were designed for ... sets of PCRs to identify the desired ... performed in a 96-well "Master Plate," where ... clones. Having identified the positive well(s) by ...
Biology Products: